Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: Association with tumor progression

Gynecologic Oncology

Volumn 107, Issue 2, 2007, Pages 266-273

  Koensgen, Dominique ^a   Mustea, Alexander ^a   Klaman, Irina ^b   Sun, Pengming ^c   Zafrakas, Menelaos ^d   Lichtenegger, Werner ^a   Denkert, Carsten ^a   Dahl, Edgar ^d   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Institute of Pathology   (Germany)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Ovarian cancer; PAI 1; PAI RBP1; SERBP1

Indexed keywords

DOXORUBICIN; MESSENGER RNA; PACLITAXEL; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATINUM DERIVATIVE; PROTEIN PAI RBP1; RNA; RNA BINDING PROTEIN; TOPOTECAN; TREOSULFAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; COMBINATION CHEMOTHERAPY; EXPRESSED SEQUENCE TAG; FEMALE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; METASTASIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; SERBP1 GENE; SOLID TUMOR; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETINOL-BINDING PROTEINS, CELLULAR; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 35348885702     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.06.023     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. J Epidemiol Biostat 6 (2001) 107-138
3. Lichtenegger W., Sehouli J., Buchmann E., et al. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res 24 (1998) 447-451
4. Conte P.F., Gadducci A., and Cianci C. Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer 11 (2001) 52-56
5. Andreasen P.A., Kjoller L., Christensen L., et al. The urokinase-type plasminogen activator system in cancer metastasis. a review. Int J Cancer 72 (1997) 1-22
6. Nykjaer A., Conese M., Christensen E.I., et al. Recycling of the urokinase receptor upon internalization of uPA:Serpin complexes. EMBO J 16 (1997) 2610-2620
7. Cubellis M.V., Wun T.C., and Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9 (1990) 1079-1085
8. Berger D.H. Plasmin/plasminogen system in colorectal cancer. World J Surg 26 (2002) 767-771
9. Nekarda H., Siewert J., Schmitt M., et al. Tumor-associated proteolytic factors u-PA and PAI-1 and survival in totally resected gastric cancer. Lancet 343 (1994) 117
10. Foekens J.A., Schmitt M., van Putten W.L.J., et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52 (1992) 6101-6105
11. Kobayasi H., Fujishiro S., and Terao T. Impact of urokinase type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54 (1994) 6539-6548
12. Janicke F., Prechtl A., Thomssen C., et al. German N0 Study Group. Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type-1. J Natl Cancer Inst 93 (2001) 913-920
13. Look M.P., van Putten W.L., Duffy M.J., et al. Pooled analysis of prognostic impact of u-PA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94 (2002) 116-128
14. Harbeck N., and Thomssen C. u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast. Zentralbl Gynakol 125 (2003) 362-367
15. Pujade-Lauraine E., Lu H., Mirshahi S., et al. The plasminogen-activation system in ovarian tumors. Int J Cancer 55 (1993) 27-31
16. Kuhn W., Pache L., Schmalfeldt B., et al. Urokinase (u-PA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55 (1994) 401-409
17. Schmalfeldt B., Kuhn W., Reuning U., et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 55 (1995) 3958-3963
18. Van der Burg M.E.L., Henzen-Logmans S.C., Berns .E.M.J.J., et al. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int J Cancer (Pred Oncol) 69 (1996) 475-479
19. Chambers S.K., Ivins C.M., and Carangiu M.L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79 (1998) 449-454
20. Hoffmann G., Pollow K., Weikel W., et al. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin Chem Lab Med 37 (1999) 47-54
21. Kuhn W., Schmalfeldt B., Reuning U., et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79 (1999) 1746-1751
22. Tecimer C., Doering D.L., Goldsmith L.J., et al. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer 10 (2000) 372-381
23. Borgfeldt C., Hansson S.R., Gustavsson B., et al. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer 92 (2001) 497-502
24. Konecny G., Untch M., Pihan A., et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 7 (2001) 1743-1749
25. Schmalfeldt B., Prechtel D., Härting K., et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7 (2001) 2396-2404
26. Heaton J.H., Dlakic W.M., Dlakic M., et al. Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor mRNA. J Biol Chem 276 (2001) 3341-3347
27. Heaton J.H., Dlakic W.M., and Gelehrter T.D. Posttranscriptional regulation of PAI-1 gene expression. Thromb Haemost 89 (2003) 959-966
28. Lemos T.A., Passos D.O., Nery F.C., et al. Characterization of a new family of proteins that interact with the C-terminal region of the chromatin-remodeling factor CHD-3. FEBS Lett 533 (2003) 14-20
29. Schmitt A.O., Specht T., Beckmann G., et al. Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues. Nucleic Acids Res 27 (1999) 4251-4260
30. Koensgen D., Sehouli J., Mustea A., et al. A new tumour documentation tool-intraoperative mapping of ovarian cancer (IMO). J Cancer Res Clin Oncol PO583 (2004) 125
31. Sehouli J., Koensgen D., Mustea A., et al. "IMO"-intraoperative mapping of ovarian cancer. Zentralbl Gynakol 125 (2003) 129-135
32. Chekerov R., Klaman I., Zafrakas M., et al. Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia 8 (2006) 38-45
33. Remmele W., and Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8 (1987) 138-140